By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Isarna Therapeutics 

Josef-Engert-Strasse 9

Regensburg    D-93053  Germany
Phone: 49-941-9201-30 Fax: 49-941-9201-329


Company News
Isarna Therapeutics Presents Positive Clinical Data For ISTH0036 In Advanced Glaucoma And Preclinical Data Supportive Of AMD/DME Potential At ARVO 2017 Annual Conference 5/15/2017 7:56:04 AM
Isarna Therapeutics Presents First Interim Phase I Data For ISTH0036 In Advanced Glaucoma At Association for Research in Vision & Ophthalmology 2016 Annual Conference 5/4/2016 11:03:58 AM
Isarna Therapeutics And Autotelic Signed Asset Sale And Purchase Agreement For Trabedersen 10/14/2015 11:59:23 AM
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015 8:40:30 AM
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015 9:30:47 AM
Isarna Therapeutics Presents Positive Preclinical Results Supporting Development Of ISTH0036 For The Treatment Of Glaucoma 5/11/2015 10:59:23 AM
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015 11:00:14 AM
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015 11:05:47 AM
Isarna Therapeutics Raises Euro 5.5 Million, Announces Elizabeth Czerepak Joining As CFO/CBO To Lead U.S. Site 4/24/2014 9:55:21 AM
Isarna Therapeutics Enters Into A Strategic Manufacturing Agreement With Sanofi (France) (SAN.PA) 1/9/2014 12:50:53 PM